Where should we enter?
Market attractiveness, demand, competitive environment and investment logic, assessed per market rather than treated as a single continental decision.
Know where to enter.
Know what it takes.
Veltrion helps pharmaceutical, diagnostics, medtech and healthcare companies assess African market opportunities, determine the regulatory and commercial pathway, qualify local counterparties and move approved opportunities toward market entry.
- Who we act for
- The manufacturer. Veltrion represents the commercial interest of the company entering the market, not the counterparties it will need.
- What we are not
- Not a distributor, not a CRO, not a law firm. Where those are required, they are engaged under a structure we help you govern.
- Where we work
- Twelve African markets under structured review, covering Southern, East and West Africa.
Six questions decide whether an African market is worth entering. They are usually answered by six different people.
Regulatory advice, commercial assessment and local counterparty selection are normally bought separately, so no one is accountable for whether the answers agree. Veltrion connects them into a single view management can act on.
01
Product
Classification, comparators and the form in which the dossier exists today.
02
Market
Demand, competitive position, procurement structure and investment logic.
03
Regulatory route
National, reliance or regional work-sharing, and what each one costs in time.
04
Access
Pricing, reimbursement, tender cycles and who actually pays for the product.
05
Counterparty
The local applicant, responsible entity, distributor and depot the market requires.
06
Commercial decision
Enter, sequence, or decline. Each with the reasoning attached.
The questions a board actually asks.
Can we register efficiently?
The applicable regulatory route, whether a reliance or work-sharing pathway is available for your product, the local roles the law requires, and realistic timing against submission cycles.
Can the market pay?
Pricing, reimbursement, procurement and tender structure, and the commercial constraints that determine whether an approved product is a purchasable one.
Who should represent us locally?
Assessment of distributors, depots, local applicants and responsible entities, including what happens to the registration if the relationship ends.
What should happen next?
A sequenced market plan built around the decision management approves, including the markets we recommend you do not spend money on yet.
What each market requires of a foreign sponsor.
In every market below, a foreign manufacturer cannot hold its own registration. Each requires a locally incorporated applicant, a local responsible entity and a locally contactable safety point. What differs is the route, the reliance position and the dossier language.
Indicative and prepared for orientation. Requirements, timelines and pathway eligibility are product-specific and change over time. This module does not constitute regulatory or legal advice, and applicability to a specific product is confirmed as part of an assessment rather than asserted here. Full detail for each market is published on its market page.
Market Selection & Access Route Assessment
A bounded first engagement with a defined scope and a fixed fee, so management gets a structured answer before committing to a market. Creditable against the mandate that follows.
| Covers | What you receive |
|---|---|
| Market attractiveness | Demand, competitive position and investment logic per market, with the markets we recommend deferring. |
| Regulatory route | The applicable pathway per market, reliance and work-sharing eligibility, and the local roles required before filing. |
| Pricing and access | Reimbursement, procurement and tender constraints that determine whether the product can be bought. |
| Counterparty requirements | The local positions each market requires, the qualification criteria, and candidate categories. |
| Material risks | What would stop this, stated plainly, including where the evidence is thin. |
| Recommended next step | A sequenced plan written to be circulated internally without translation. |
One accountable market interface. Specialist capability where required.
Veltrion is a focused core that holds the mandate and the accountability. Specialist and local capability is contracted underneath it and governed centrally, so you deal with one counterpart rather than assembling five.
- The mandateScope, sequence and the commercial recommendation.
- Market and route assessmentWhich markets, which pathway, in what order.
- Counterparty qualificationAssessment and selection criteria for local parties.
- Governance of the structureWho is accountable for what, and what happens if a relationship ends.
- Regulatory specialistsDossier preparation and authority engagement in-market.
- Local commercial counterpartiesApplicants of record, responsible entities, distributors and depots.
- Clinical infrastructureSites, investigators and trial supply, where a study is in scope.
- Legal counselInstructed separately by you. Veltrion is not a law firm and does not provide legal services.
What this is built on.
South Africa in Clinical Trial Supply: An Underrecognized Capability — published industry commentary on South African clinical supply infrastructure.
A decade inside clinical research before the practice was established, across trial delivery and the regulatory and supply interfaces that determine whether a study runs.
Twelve African markets maintained under structured review, covering the authority, local representation requirement, trial route, reliance position and dossier language for each.
Veltrion Laboratories (Pty) Ltd, registration 2026/155300/07, Cape Town, South Africa. Governance policies are published in full.
Tell us the market and the decision you are facing.
Most of these resolve in one call. If there is no route worth taking, we will say so on the call rather than sell you an assessment.